Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EBITDA (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of EBITDA readings, the most recent being -$58.7 million for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 60.6% year-over-year to -$58.7 million, compared with a TTM value of $23.6 million through Dec 2025, up 111.94%, and an annual FY2025 reading of $23.6 million, up 111.94% over the prior year.
  • EBITDA hit -$58.7 million in Q4 2025 for Apellis Pharmaceuticals, down from $215.9 million in the prior quarter.
  • The five-year high for EBITDA was $215.9 million in Q3 2025, with the low at -$219.4 million in Q2 2021.
  • Median EBITDA over the past 5 years was -$130.5 million (2022), compared with a mean of -$105.2 million.
  • The sharpest move saw EBITDA tumbled 285.23% in 2021, then soared 477.27% in 2025.
  • Year by year, EBITDA stood at -$148.0 million in 2021, then dropped by 10.69% to -$163.8 million in 2022, then skyrocketed by 44.43% to -$91.1 million in 2023, then skyrocketed by 59.89% to -$36.5 million in 2024, then tumbled by 60.6% to -$58.7 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$58.7 million, $215.9 million, and -$41.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.